The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

Download Free Sample Pages of this report

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2019-2029

Profiles of the leading 20 asthma & COPD companies:

  • Aerocrine (Circassia)
  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cipla
  • GlaxoSmithKline
  • Lallemand Pharma International
  • Merck
  • MundiPharma
  • Novartis
  • Pulmatrix
  • Roche
  • Sanofi/Regeneron
  • Sunovion
  • Teva
  • Theravance Biopharma|Mylan Inc.
  • Vectura Group plc
  • Verona Pharma plc

The content of each profile differs, depending on the organization. In general, a profile gives the following information:

  • An overview and analysis of the company
  • A portfolio of the company’s marketed product and product pipeline
  • Financial Information
  • Revenue forecast from 2019-2029
  • Recent developments
  • Future Outlook

This report discusses factors that drive and restrain the asthma and COPD market.

This study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.